Asieris(SH:688176) 智通财经网·2025-10-10 08:24Core Viewpoint - APL-1702, a product developed by the company for treating High-Grade Squamous Intraepithelial Lesion (HSIL), has had its Phase III clinical trial results published in the prestigious journal "Med" by Cell Press, indicating a significant step in the product's development [1][2] Group 1: Product Information - APL-1702 is a photodynamic therapy product that combines drug and device components, designed as a non-surgical local treatment for HSIL [2] - The product consists of APL-1702 ointment and a device, currently under review by the National Medical Products Administration (NMPA) in China [2] Group 2: Clinical Trial and Publication - The results of the international, multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial for APL-1702 have been published online in "Med," a top-tier journal in the medical field [1] - "Med" is recognized as a flagship journal of Cell Press, following "Cell" and "Chem," and is classified as a Q1 journal in the Journal Citation Reports (JCR) [1] Group 3: Market and Regulatory Considerations - The approval and market launch of APL-1702 remain uncertain as it is still undergoing the review process by the NMPA, with potential commercial success also being uncertain [2] - The publication of the clinical trial data is not expected to have a significant impact on the company's recent performance [2]